

CLINICAL PRACTICE

Caren G. Solomon, M.D., M.P.H., *Editor*

Measles

Peter M. Strebel, M.B., Ch.B., M.P.H., and Walter A. Orenstein, M.D.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors' clinical recommendations.

A 38-year-old man presents to his primary care physician with a 3-day history of fever and cough. He is a father of two children, his wife is pregnant, and he has a history of recent travel outside the United States. The physical examination is notable for a body temperature of 39°C, conjunctivitis, and rhonchi on chest auscultation. The physician suspects bronchitis and prescribes antibiotic agents. Two days later, the patient returns with a red blotchy rash over his face and trunk. The physician becomes concerned about the possibility of measles. How should this case be further evaluated and managed? How might measles have been prevented, and what can be done to prevent the spread of the disease within the patient's family and community?

THE CLINICAL PROBLEM

MEASLES VIRUS IS ONE OF THE MOST HIGHLY CONTAGIOUS HUMAN pathogens known. In a 100% susceptible population, a single case of measles results in 12 to 18 secondary cases, on average.¹ Two doses of measles-containing vaccine is the standard of care for the prevention of measles.²

MEASLES IN THE UNITED STATES

Measles vaccine was first licensed in the United States in 1963, after which the incidence of measles declined rapidly (Fig. 1). Measles was certified as eliminated in the United States (i.e., no sustained transmission for >1 year) in 2000.³ Strategies for elimination included achieving and maintaining very high coverage with two doses of measles-containing vaccine, implementation of vaccination requirements for school attendance in every state, sensitive laboratory-supported surveillance, and rapid outbreak detection and response.⁴

Although the incidence of measles has remained lower than 1 case per million population, an analysis of confirmed cases in the United States between 2001 and 2015 showed that importations were leading to progressively more transmission in the United States, particularly among unvaccinated persons.⁵ From 2001 to 2016, a median of 28 imported cases of measles were documented each year (range, 18 to 80); among the persons with imported cases, 62% were U.S. residents and 87% were unvaccinated or had an unknown vaccination status.⁶ Since 2016, a year in which 86 cases of measles were confirmed in the United States, the annual number of cases has increased. The number of cases reported so far this year (1077 as of June 20, 2019) is greater than the number reported in any entire year since measles was declared eliminated in 2000 and, in fact, exceeds the number of cases in any entire year since 1992 (Fig. 1). The high number of cases in 2019 is heavily

From Gavi, the Vaccine Alliance, Global Health Campus, Geneva (P.M.S.); and Emory University and the Emory Vaccine Center, Atlanta (W.A.O.). Address reprint requests to Dr. Strebel at Gavi, the Vaccine Alliance, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland, or at pstrebel@gavi.org.

This article was published on July 10, 2019, at NEJM.org.

DOI: 10.1056/NEJMc1905181

Copyright © 2019 Massachusetts Medical Society.




**An audio version
of this article
is available at
NEJM.org**

KEY CLINICAL POINTS

MEASLES

- Clinicians should suspect measles in persons who have a febrile illness with rash, especially if they lack documentation of measles vaccination, have recently traveled overseas, or are part of a community with low vaccine acceptance.
- Clinical specimens (e.g., serum and nasopharyngeal swab) for laboratory confirmation should be obtained from all patients suspected to have measles at their first contact with a health care provider.
- All suspected cases of measles should be reported immediately to the local or state health department without waiting for diagnostic test results.
- U.S. travelers to other countries account for a high proportion of imported cases of measles, which emphasizes the importance of measles vaccination of U.S. residents who are 6 months of age or older before international travel.
- Serious adverse events after measles–mumps–rubella vaccination are rare and much less common than those associated with natural measles infection.
- Clinicians play a critical role in managing parental concerns about vaccination and in maintaining trust in vaccines.



influenced by three outbreaks that started in late 2018 — one in Washington State and two in New York — in close-knit, underimmunized communities.⁷ These outbreaks are linked to travelers who brought measles back from other countries such as Israel, Ukraine, and the Philippines, where large measles outbreaks are occurring. The Centers for Disease Control and Prevention (CDC) reported that an important factor contributing to the outbreaks in New York is misinformation in the communities about the safety of the measles–mumps–rubella (MMR) vaccine.⁸

MEASLES GLOBALLY

Between 2000 and 2017, the global annual incidence of reported cases of measles declined by 83%, from 145 to 25 cases per million population. In 2017, it is estimated that there were 109,000 deaths from measles worldwide, down from 545,000 in 2000; cumulatively during this period, as compared with no measles vaccination, measles vaccination prevented an estimated 21.1 million deaths.⁹ Recent increases in the incidence of measles in the United States and other industrialized countries are part of a global

upswing in reported cases of measles that began in 2018 and is continuing into 2019. Countries with the largest numbers of reported cases over the most recent 6-month period include Madagascar, Ukraine, India, Brazil, Philippines, Venezuela, Thailand, Kazakhstan, Nigeria, and Pakistan.¹⁰ Although the vast majority of cases worldwide occur in countries with weak health systems, vaccine refusal is emerging as a risk factor for measles outbreaks, and the World Health Organization (WHO) has identified vaccine hesitancy as one of the top 10 global health threats in 2019.¹¹

All six WHO regions have the goal of measles elimination by or before 2020. The Americas is the only region that had been verified to be free of endemic measles. However, an outbreak of measles that started in Venezuela in 2017 is still ongoing, indicating that endemic measles transmission has been reestablished in the Americas.¹²

STRATEGIES AND EVIDENCE

CLINICAL PRESENTATION

Measles is an acute viral illness that starts with a prodromal phase, lasting 2 to 4 days, of fever and at least one of the “three Cs” (cough, coryza, and conjunctivitis), similar to any upper respiratory tract infection.¹³ The characteristic measles rash — an erythematous maculopapular exanthem — appears 2 to 4 days after the onset of fever, first on the face and head and then on the trunk and extremities; it may be confluent on the face and upper body (Fig. 2). During the ensuing 3 to 5 days, the rash in different parts of the body fades in the order in which it appeared, and full recovery occurs within 7 days after rash onset in uncomplicated cases. Koplik spots, small bluish white plaques on the buccal mucosa, are present in up to 70% of cases and are considered pathognomonic of measles; they may appear 1 to 2 days before the onset of rash and may be present for an additional 1 to 2 days after rash onset (Fig. 2).¹⁵

Complications associated with measles infection in industrialized countries include otitis media (7 to 9% of patients), pneumonia (1 to 6%), diarrhea (8%), postinfectious encephalitis (approximately 1 per 1000), subacute sclerosing panencephalitis (a progressive degenerative disease with onset usually 5 to 10 years after acute measles; approximately 1 per 10,000), and death (approximately 1 per 1000). The risk of complications is increased among infants, adults older

than 20 years of age, pregnant women, undernourished children (particularly those with vitamin A deficiency), and persons with immune suppression (e.g., cancer or human immunodeficiency virus [HIV] infection). An acute progressive encephalitis (measles inclusion-body encephalitis¹⁶) and a characteristic giant-cell pneumonia (Hecht’s pneumonia¹⁷) are two especially severe complications that may occur in rare cases in persons with immune suppression.

Measles runs a more devastating course in children in developing countries, a phenomenon related to undernutrition, overcrowding, and lack of access to care, with mortality as high as 1 to 15%.¹⁸ Measles infection during pregnancy is associated with an increased risk of complications, including miscarriage, preterm birth, neonatal low birth weight, and maternal death.¹⁹

DIAGNOSIS

Whereas a typical case of measles is easily recognized during outbreaks, the clinical diagnosis is challenging to many clinicians who have not seen measles and in patients who present before the onset of rash or whose rash is less apparent (e.g., infants with residual maternally acquired antibodies, previous receipt of immunoglobulin, or vaccination after exposure). The typical measles rash may be absent in persons with impaired cell-mediated immunity.²⁰

The differential diagnosis includes rubella, dengue fever, parvovirus B19 infection, human herpesvirus 6 infection, and other infections, as well as reactions to measles vaccine. The measles case definition recommended by the CDC (i.e., generalized maculopapular rash, fever [body temperature, $\geq 38.3^{\circ}\text{C}$], and cough, coryza, or conjunctivitis [or a combination of these symptoms]) has a high sensitivity (75 to 90%) but a low positive predictive value in low-incidence settings, indicating the need for laboratory confirmation.²¹

The most common laboratory method for confirming measles is detection of measles virus-specific IgM antibodies in a blood specimen (sensitivity, 83 to 89%; specificity, 95 to 99%).²² These antibodies are not detectable in approximately 25% of persons within the first 72 hours after rash onset but are almost always present after 4 days of rash. A real-time polymerase-chain-reaction (PCR) assay for measles virus RNA in urine, blood, oral fluid, or nasopharyngeal spec-



Figure 2. Manifestations of Measles in Children.

Panel A shows an infant with measles conjunctivitis and rash. Patients with measles rash are shown in Panels B, C, and D. In Panel B, pigmentation and desquamation of the measles skin rash (complications that are most often seen in undernourished children) are visible; these signs are evident approximately 5 days after the onset of rash and may continue for weeks. Panel E shows a patient with Koplik spots on the buccal mucosa. Panels A and D were provided by M. Bring of the World Health Organization (WHO), Panel B by the WHO,¹⁴ Panel C by U. Sharapov of the Centers for Disease Control and Prevention (CDC), and Panel E by the Office of the Associate Director for Communications, Division of Public Affairs, CDC.

imens can identify infection with a sensitivity of 94% and a specificity of 99%²³ before measles IgM antibodies are detectable, and it allows geno-

typing of the measles virus, which is useful for tracking virus importations and spread.²⁴ All cases of suspected measles should be reported

immediately — without waiting for diagnostic test results — to the local or state health department, which can assist with obtaining tests and take actions to minimize spread of virus.

MANAGEMENT

Because there is no specific antiviral medication available, treatment of measles consists of supportive therapy to prevent dehydration and, in some cases, to treat nutritional deficiencies, as well as early detection and treatment of secondary bacterial infections such as pneumonia and otitis media. High doses of vitamin A have been shown to decrease mortality and the risk of complications in young children hospitalized with measles in developing countries.²⁵ In the United States, children with measles have been found to have low levels of serum retinol, and levels tend to be lower among those with more severe illness.²⁶ The American Academy of Pediatrics (AAP) recommends vitamin A administration for all children with severe measles (e.g., requiring hospitalization), with the use of the following age-specific doses: 200,000 IU for children 12 months of age or older; 100,000 IU for infants 6 to 11 months of age; and 50,000 IU for infants younger than 6 months.²⁷ A third age-specific dose should be given 2 to 4 weeks later to children who have clinical signs and symptoms of vitamin A deficiency. In addition, vitamin A therapy should be administered to children with measles who have immunosuppression, have clinical evidence of vitamin A deficiency, or have recently immigrated from areas with a high mortality from measles. Antibiotics, in the absence of pneumonia, sepsis, or other signs of a secondary bacterial complication, are generally not recommended.²⁸ To prevent nosocomial transmission, patients who are suspected to have measles should be triaged in outpatient settings, and hospitalized patients with measles should be isolated with precautions to prevent airborne transmission.²⁷ Patients with measles are infectious from 4 days before to 4 days after the onset of their rash.

POSTEXPOSURE PROPHYLAXIS

Measles vaccine given within 72 hours after measles exposure, or human immune globulin given up to 6 days after exposure, can prevent or attenuate disease in susceptible persons.²⁹ In household or classroom settings in which the timing

of first exposure can be determined, prophylaxis has been shown to be highly effective (up to 90% after vaccine³⁰ and 95% after immune globulin³¹). Measles-containing vaccine should be considered for all exposed persons who do not have contraindications and who have not been vaccinated or have received only one dose of vaccine.

Administration of immune globulin is particularly critical for patients who are at risk for severe disease, including infants younger than 12 months of age, pregnant women without evidence of measles immunity, and severely immunocompromised persons. The Advisory Committee on Immunization Practices recommends a dose of 0.5 ml per kilogram of body weight administered intramuscularly for persons with a body weight of up to 30 kg and a dose of 400 mg per kilogram intravenously for persons weighing more than 30 kg.²⁹ Because the immunity to measles conferred by administration of immune globulin is temporary, persons who receive immune globulin should subsequently receive MMR vaccine, administered no earlier than 6 months after intramuscular immune globulin or 8 months after intravenous immune globulin.

Severely immunocompromised patients (e.g., bone marrow transplant recipients, as well as persons who have acquired immunodeficiency syndrome or HIV infection with severe immunosuppression and those who have not received MMR vaccine since receiving effective antiretroviral therapy) who are exposed to measles should receive prophylaxis with intravenous immune globulin regardless of their immunologic or vaccination status, because they might not have been protected by vaccination.²⁹

VACCINE EFFECTIVENESS

Field studies of the effectiveness of the measles vaccine have found high effectiveness after one dose administered at the age of 12 months or later (median effectiveness, 93%; range, 39 to 100) and even higher effectiveness after two doses (median, 97%; range, 67 to 100).²⁹ The WHO recommends two doses of measles-containing vaccine as the standard of care for the prevention of measles in all countries.² Two doses are needed to reach herd-immunity thresholds and terminate transmission. Vaccine-induced immunity is probably lifelong in the vast majority of vaccinees.³²

Table 1. Comparison of the Risk of Complications Associated with Measles and the Risk of Serious Adverse Events after Measles Vaccination.*

| Complication or Serious Adverse Event | Risk after Natural Disease† | Risk after Vaccination‡ |
|---------------------------------------|--|-------------------------|
| Otitis media | 7 to 9 per 100 | 0 |
| Diarrhea | 8 per 100 | 0 |
| Pneumonia | 1 to 6 per 100 | 0 |
| Subacute sclerosing panencephalitis | 4 to 11 per 100,000 | 0 |
| Encephalitis | 0.5 to 1 per 1000 | <1 per 1,000,000 |
| Death | Approximately 1 per 1000 (1 to 15 per 100 in developing countries) | 0 |
| Febrile seizure | —§ | 1 per 3000 |
| Thrombocytopenic purpura | —§ | 1 per 30,000 |
| Anaphylaxis | 0 | 2 to 14 per 1,000,000 |

* Information is from the Institute of Medicine³⁵ and Pless et al.³⁶

† Risk is expressed as the number of events per number of cases of measles.

‡ Risk is expressed as the number of events per number of vaccine doses administered.

§ Complication has been described in measles case reports, but the risk is not well quantified.

VACCINE SAFETY

After 50 years of licensure and with more than 100 million doses administered worldwide each year since 2000, measles-containing vaccines have a well-established safety record. The MMR vaccine has an acceptable side-effect profile. Adverse events include fever (<15% of recipients), transient rashes occurring 7 to 12 days after vaccination (5%), transient lymphadenopathy (5% of children and 20% of adults), parotitis (<1%), and aseptic meningitis (1 to 10 per million).^{33,34} Serious adverse events are rare and much less common than the risks associated with natural measles infection; these include anaphylaxis (2 to 14 cases per million doses), febrile seizures (1 case per 3000 doses), thrombocytopenic purpura (1 case per 30,000 doses), and measles inclusion-body encephalitis in persons with demonstrated immunodeficiencies (Table 1).^{35,36} The rubella component of MMR can cause transient arthralgia or arthritis, primarily in susceptible postpubertal female patients.

Antivaccine groups continue to postulate that the MMR vaccine may be a cause of inflammatory bowel disease and autism on the basis of a case series published in 1998 that was later retracted because of falsification of clinical information.³⁷ Subsequent laboratory and epidemiologic studies have not supported an association between the MMR vaccine and these conditions.^{38,39}

GENERAL RECOMMENDATIONS FOR MEASLES VACCINATION

Measles-control programs throughout the world have shown that measles is eliminated if national immunization schedules are fully implemented and high vaccination coverage is achieved and maintained, whereas measles outbreaks occur when populations are not adequately vaccinated. The U.S. recommendations²⁹ are shown in Table 2; schedules for other countries can be found at http://apps.who.int/immunization_monitoring/globalsummary/schedules.

In addition to ongoing vaccination of new birth cohorts, prevention of measles outbreaks requires the identification and vaccination of persons who are at high risk on the basis of exposure or contact frequency (e.g., school-attending children, college students, international travelers, and health care workers) and others who are more likely to have missed both vaccination and natural infection, such as persons from underserved or geographically or socially isolated communities.

In the United States, the only measles-containing vaccines are the MMR vaccine and the combined measles–mumps–rubella–varicella (MMR-V) vaccine. The CDC recommends that the MMR and varicella vaccines be administered separately for the first dose, but they can be given as the MMR-V for the second dose.²⁹ MMR is the vaccine of choice for the prevention of measles in

Table 2. Summary of Measles Vaccination Recommendations in the United States.*

| Age Group | Vaccination Recommendation |
|--|--|
| Preschool children | |
| Routine childhood schedule | First dose at 12 to 15 months (MMR vaccine); second dose at 4 to 6 years (MMR-V vaccine) |
| Outbreak settings or before international travel | First dose may be given as early as 6 months, with repeat of first dose at 12 months; second dose given as early as 13 months† |
| HIV infection | First dose at 12 months; second dose given as early as 13 months†‡ |
| Schoolchildren and adolescents | All children in kindergarten through 12th grade should have documentation of two doses of MMR unless they have other evidence of immunity§ |
| Adults (≥18 years of age) | Documentation of receipt of at least one dose of MMR unless they have other evidence of immunity§ |
| High-risk settings | Students and staff in colleges and other post-high school educational institutions, persons working in health care facilities, and international travelers should have documentation of receipt of two doses of measles vaccine unless they have other evidence of immunity§ |

* Information is from McLean et al.²⁹ All recommendations exclude persons for whom measles vaccination is contraindicated. MMR denotes measles–mumps–rubella, and MMR-V measles–mumps–rubella–varicella.

† Clinicians should wait at least 28 days after any dose before giving a subsequent dose.

‡ Revaccination is recommended for persons with perinatal human immunodeficiency virus infection who were vaccinated before establishment of effective antiretroviral therapy (ART) with two appropriately spaced doses of MMR vaccine after effective ART has been established.

§ Other evidence can include birth before 1957 or laboratory confirmation of disease or laboratory evidence of immunity.

adolescents and adults and in infants 6 to 11 months of age who are at increased risk for exposure (e.g., during outbreaks or international travel) (Table 2). Recommendations regarding acceptable evidence of immunity are available to guide decisions about who should or should not be vaccinated against measles (Table 3).

AREAS OF UNCERTAINTY

Antiviral agents (e.g., ribavirin and interferon) have been used to treat severely affected and immunocompromised patients with measles, and positive outcomes have been reported.⁴¹ However, randomized controlled trials are lacking, and ribavirin is not licensed by the Food and Drug Administration for the treatment of measles. Further research is needed to determine the benefits and risks of antiviral agents in the treatment of severe cases of measles.

Although measles meets the criteria for a disease that can be eradicated, strategies are needed to increase and maintain uptake of recommended vaccine schedules. Study is needed of new vaccine-delivery technologies (e.g., microarray patches) or new vaccines that could improve on the current two-dose strategies.

GUIDELINES

Guidelines have been published by the AAP²⁷ and the WHO¹⁴ on management of measles and by the CDC²⁹ and the WHO² on the use of measles vaccine and immune globulin. The recommendations in the present article are concordant with these guidelines.

CONCLUSIONS AND RECOMMENDATIONS

Clinicians should suspect measles in an infant, child, adolescent, or adult who has a febrile rash illness, especially if the person lacks documentation of measles vaccination, has traveled overseas (as the patient described in the vignette did) or is part of a community with low vaccine acceptance. Once measles is suspected, the clinician should immediately contact the state or local health department, which can provide advice regarding clinical specimens for laboratory diagnosis, treatment of household contacts, and follow-up of contacts to determine the need for vaccine or immune globulin. If the patient's wife, who is pregnant, lacks evidence of immunity to measles, she should receive intravenous immune globulin

Table 3. Centers for Disease Control and Prevention Recommendations for Acceptable Evidence of Immunity to Measles in the United States.*

| Type of Evidence | Age Group | Comments |
|---|--|--|
| Written documentation of vaccination with live measles-containing vaccine | Preschool-age children (documentation of one dose) School-age children, kindergarten through 12th grade (documentation of two doses) Adults not at high risk (documentation of one dose) Adults at high risk (documentation of two doses) | Date of vaccination should appear on the vaccination card or in medical records. Adults at high risk include all students in post-high school educational institutions, health care personnel, and international travelers. |
| Laboratory evidence of immunity | All ages | Immunity is indicated by positivity for measles IgG. |
| Laboratory evidence of prior measles | All ages | A previous case of measles should have been confirmed by measles IgM positivity, IgG seroconversion or a substantial increase in measles IgG between acute- and convalescent-phase serum specimens, or a positive PCR result. |
| Date of birth | Born before 1957 | Persons born before 1957 are assumed to have acquired measles during childhood and therefore to be immune. |

* Information is from McLean et al.²⁹ and Gastanaduy et al.⁴⁰ Persons who do not have at least one of the criteria listed should be vaccinated. PCR denotes polymerase chain reaction.

because of the complications of measles in pregnancy and the hypothetical risk of live vaccines during pregnancy.⁴² If either of the patient's children are unvaccinated or have received only one dose, they should be vaccinated with the MMR vaccine as soon as possible. To avoid further spread of measles in his community, the patient should be isolated at home for 4 days after the onset of his rash.

To minimize the risk of new cases and outbreaks, clinicians should advise patients who are planning international travel about indications for measles vaccination. With the increasing spread of inaccurate information regarding vac-

cine-associated risks on social media, clinicians play a key role in responding to questions from patients regarding the rationale for, and safety of, the MMR vaccine, as well as in maintaining trust in vaccination among their patients and their families. Comprehensive guidance for clinicians about managing parental concerns about vaccination is available in a recent AAP publication⁴³ and in online material from the CDC (www.cdc.gov/measles/index.html).

No potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

REFERENCES

- Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. *J Infect Dis* 2004;189: Suppl 1:S27-S35.
- World Health Organization. Measles vaccines: WHO position paper—April 2017. *Wkly Epidemiol Rec* 2017;92:205-27.
- Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16-17 March 2000. *J Infect Dis* 2004;189: Suppl 1:S43-S47.
- Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. *J Infect Dis* 2004;189:Suppl 1:S1-S3.
- Clemmons NS, Wallace GS, Patel M, Gastanaduy PA. Incidence of measles in the United States, 2001-2015. *JAMA* 2017; 318:1279-81.
- Lee AD, Clemmons NS, Patel M, Gastanaduy PA. International importations of measles virus into the United States during the post-elimination era, 2001-2016. *J Infect Dis* 2019;219:1616-23.
- Patel M, Lee AD, Redd SB, et al. Increase in measles cases—United States, January 1–April 26, 2019. *MMWR Morb Mortal Wkly Rep* 2019;68:402-4.
- Measles cases and outbreaks: measles cases in 2019. Atlanta: Centers for Disease Control and Prevention, 2019 (<https://www.cdc.gov/measles/cases-outbreaks.html>).
- Dabbagh A, Laws RL, Steulet C, et al. Progress toward regional measles elimination—worldwide, 2000-2017. *MMWR Morb Mortal Wkly Rep* 2018;67:1323-9.
- World Health Organization. Immunization, vaccines and biologicals: new measles surveillance data for 2019 (<https://www.who.int/immunization/newsroom/measles-data-2019/en/>).
- World Health Organization. Ten threats to global health in 2019 (<https://www.who.int/emergencies/ten-threats-to-global-health-in-2019/>).
- Strategic Advisory Group of Experts on Immunization. 2018 Assessment report of the Global Vaccine Action Plan. Geneva: World Health Organization, 2018 (https://www.who.int/immunization/global_vaccine_action_plan/SAGE_GVAP_Assessment_Report_2018_EN.pdf).
- Moss WJ. Measles. *Lancet* 2017;390: 2490-502.

14. World Health Organization. Treating measles in children: WHO/EPI/TRAM/97.02. 2004 (https://www.who.int/immunization/programmes_systems/interventions/TreatingMeaslesENG300.pdf).
15. Xavier S, Forgie SED. Koplik spots revisited. *CMAJ* 2015;187:600.
16. Griffin DE. Measles virus and the nervous system. *Handb Clin Neurol* 2014;123:577-90.
17. Enders JF, McCarthy K, Mitus A, Cheatham WJ. Isolation of measles virus at autopsy in cases of giant-cell pneumonia without rash. *N Engl J Med* 1959;261:875-81.
18. Wolfson LJ, Grais RF, Luquero FJ, Birmingham ME, Strebel PM. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. *Int J Epidemiol* 2009;38:192-205.
19. Ogbuanu IU, Zeko S, Chu SY, et al. Maternal, fetal, and neonatal outcomes associated with measles during pregnancy: Namibia, 2009-2010. *Clin Infect Dis* 2014;58:1086-92.
20. Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. *Clin Infect Dis* 1999;29:106-12.
21. Hutchins SS, Papania MJ, Amler R, et al. Evaluation of the measles clinical case definition. *J Infect Dis* 2004;189:Suppl 1:S153-S159.
22. Bellini WJ, Helfand RF. The challenges and strategies for laboratory diagnosis of measles in an international setting. *J Infect Dis* 2003;187:Suppl 1:S283-S290.
23. Roy F, Mendoza L, Hiebert J, et al. Rapid identification of measles virus vaccine genotype by real-time PCR. *J Clin Microbiol* 2017;55:735-43.
24. Manual for the laboratory-based surveillance of measles, rubella, and congenital rubella syndrome. 3rd ed. Geneva: World Health Organization, June 2018 (www.who.int/immunization/monitoring_surveillance/burden/laboratory/manual/en/).
25. Huiming Y, Chaomin W, Meng M. Vitamin A for treating measles in children. *Cochrane Database Syst Rev* 2005;4:CD001479.
26. Butler JC, Havens PL, Sowell AL, et al. Measles severity and serum retinol (vitamin A) concentration among children in the United States. *Pediatrics* 1993;91:1176-81.
27. Kimberlin DK, ed. 2018-2021 Red Book: report of the Committee on Infectious Diseases. 31st ed. Elk Grove Village, IL: American Academy of Pediatrics, 2018.
28. Kabra SK, Lodha R. Antibiotics for preventing complications in children with measles. *Cochrane Database Syst Rev* 2013;8:CD001477.
29. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2013;62(RR-4):1-34.
30. Barrabeig I, Rovira A, Rius C, et al. Effectiveness of measles vaccination for control of exposed children. *Pediatr Infect Dis J* 2011;30:78-80.
31. Janeway CA. Use of concentrated human serum γ -globulin in the prevention and attenuation of measles. *Bull N Y Acad Med* 1945;21:202-22.
32. Strebel PM, Papania MJ, Gastanaduy PA, Goodson JL. Measles vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. *Vaccines*. 7th ed. Philadelphia: Elsevier, 2018:579-618.
33. Duclos P, Ward BJ. Measles vaccines: a review of adverse events. *Drug Saf* 1998;19:435-54.
34. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine: a double-blind placebo-controlled trial in twins. *Lancet* 1986;1:939-42.
35. Institute of Medicine. Measles, mumps, and rubella vaccine — adverse effects of vaccines: evidence and causality. Washington, DC: National Academies Press, 2012:103-237.
36. Pless RP, Bentsi-Enchill AD, Duclos P. Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues. *J Infect Dis* 2003;187:Suppl 1:S291-S298.
37. Retraction — Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *Lancet* 2010;375:445.
38. Stratton K, Gable A, Shetty P, et al. Immunization safety review: measles-mumps-rubella vaccine and autism. Washington, DC: National Academy Press, 2001.
39. Hviid A, Hansen JV, Frisch M, Melbye M. Measles, mumps, rubella vaccination and autism: a nationwide cohort study. *Ann Intern Med* 2019;170:513-20.
40. Gastanaduy PA, Redd SB, Clemmons NS, et al. Measles. In: Roush SW, Baldy LM, Hall MAK, eds. *Manual for the surveillance of vaccine-preventable diseases*. Atlanta: Centers for Disease Control and Prevention (<https://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html>).
41. Banks G, Fernandez H. Clinical use of ribavirin in measles: a summarized review. In: Smith RA, Knight V, Smith JAD, eds. *Clinical applications of ribavirin*. New York: Academic Press, 1984:203-9.
42. Manikkavasagan G, Ramsay M. The rationale for the use of measles post-exposure prophylaxis in pregnant women: a review. *J Obstet Gynaecol* 2009;29:572-5.
43. Edwards KM, Hackell JM. Countering vaccine hesitancy. *Pediatrics* 2016;138(3):e20162146.

Copyright © 2019 Massachusetts Medical Society.